Cassondra sells NFG 74.64: Orexigen Shares Plummet Following FDA Decision; Glaxo, Theravance Report Positive Data from Two Studies Considering Efficacy
{nfg}Orexigen Therapeutics (NASDAQ: OREX) on announced that the FDA has issued a three-month extension for the review of Orexigen's new weight-loss drug, NB32.The FDA report indicated the reason for the extension was to reach an agreement on the post ... ...
17 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home